Vetnuus | February 2026 17 • Dr Baty Dungu - Member of the World Organisation for Animal Health (WOAH) Scientific Commission, African Union Pan African Veterinary Vaccine Centre (AU PANVAC) Steering Committee, and African Union – InterAfrican Bureau for Animal Resources (AU-IBAR) expert panel on animal health and disease control • Dr Danie Odendaal - Ruminant Veterinarian Specialist Dr Gerhard Neethling - Export and Abattoir Specialist • Dr Francois Maree - Specialist in vaccine design, testing, and diagnostics and Dr Livio Heath - Diagnostics, Epidemiology, and International Trade Relations. To maintain transparency and cross-sector alignment, this task team reports directly to the Value Chain Round-Tables. This structure ensures that every stakeholder - from local producers to international trade partners - is represented in the decision-making process. A Technically Rigorous Strategy The strategy we are employing is not a temporary patch; it is a comprehensive control and eradication programme designed to interrupt virus transmission and protect our national herd. It is important to emphasise that the success of this strategy will strongly rely on urgent review of the legislative framework, that has to be adapted to the current emergency situation. Our plan is built on world-class technical principles: Targeted Vaccination: We are prioritising high-risk zones, with the goal of reaching at least 80% coverage in targeted cattle populations especially the communal areas and up to 100% in feedlots and dairy cows. The objective is to reduce outbreak incidence within 12 months by more than 70% in the high-risk provinces through systematic vaccination and preserve FMD-free provinces through buffer vaccination and strict movement controls. High-Quality Vaccines with high-potency will be used during the campaign especially, trivalent vaccines of SAT 1, 2, and 3 currently circulating in South Africa. Partnerships with global leaders like Biogénesis Bagó in Argentina will ensure that we have a reliable supply, with one million doses ready to be sent as soon as the necessary permits are issued. The company indicated that as soon as the permits are issued, they are able to supply the vaccine in the coming two weeks. We are currently preparing the application for authorisation by the South African Health Products Regulatory Authority (SAHPRA) to use an unregistered medicine under Section 21 of Act 101. The application will be filed by Monday. Biogenesis will also be able to supply an additional five million doses by March 2026. Since the outbreak we have been procuring vaccine from the Botswana Vaccine Institute (BVI) and will continue sourcing vaccine from this institute. The BVI and the ARCI will look into the existing memorandum and complement one another to ensure that we reach the maximum vaccine coverage. Last year we received confirmation from the BVI that they can supply us with one million doses per month. Unfortunately, due to the closure of their factory for cleaning purposes they could not deliver on time. The delegation of Botswana was in South Africa yesterday and the have confirmed that they have the bulk antigen of SAT 2. This bulk antigen will be formulated to produce SAT 2 vaccine to be used in arears where SAT 2 is prevalent. We have also secured the one necessary permit to import Dollvet vaccine from Turkey. As indicated earlier it will take us some time to contain the disease. Locally, we are activating a local production line through the ARC and OBP, which will initially produce 20 000 doses per week , scaling up to a capacity of 960 000 doses. The ARC indicated on Monday that they can bring forward their production – which will add 12 000 doses to our vaccine pool by mid-February. Pirbright Institute – Many calls have been made, and assumptions that we have not sent our latest strains to the Pirbright Institute. However, I can confirm I instructed the ARC to send the field strains to Pirbright as a matter of urgency. The ARC confirmed they are currently preparing the strains to be sent to the institute. All FMD vaccines to be used in South Africa will have full antigenic matching at Pirbright against South Africa’s current field strains to allow comparison of the various vaccines; this will allow South Africa to select the best vaccines to contribute to the control of this devastating disease. Enhanced Surveillance & Movement Control: We are strengthening our laboratory network, led by the Agriculture Research Council – Onderstepoort Veterinary Research (ARC-OVR), which will work with existing state laboratories to ensure that results are received timeously. We have started with increasing capacity at the OVR. We will implement a digital livestock and traceability system to ensure that animal movements are safe and tracked. Other simplified mechanism will also be looked into. We are currently working with the Council for Scientific and Industrial Research (CSIR) and RMIS traceability platform to implement the Livestock Identification and Traceability System (LITS) which will enhance our traceability. With the integration of advanced technology, we are no longer fighting this disease in the dark. Through the Red Meat Industry Services (RMIS) Operational Centre, we now utilise a real-time digital heatmap to track verified cases and suspected outbreaks within a 10km radius. This work is done together with Epidemiologists from SAEHP, using resources from the equine industry. Outbreaks It is important to note that the current outbreak started in 2021 when animals moved from Phalaborwa to KwaZulu Natal. >>>18 Article
RkJQdWJsaXNoZXIy OTc5MDU=